• Lívia Dos Remédios Pamplona de Oliveira, Tarsila Campanha da Rocha Ribeiro, Carlos Alberto Mourao Junior, Maria Antônia de Lima Barra, Mariana Hippert Gonçalves Silva, Luis Pordeus Shafee, Sarah Mendes Zacarias, Lenilton da Costa Campos, Helena Maria Giordano Valério, and Júlio Maria Fonseca Chebli.
• Universidade Federal de Juiz de Fora, Hospital Universitário - Juiz de Fora (MG), Brazil.
• Rev Assoc Med Bras (1992). 2024 Jan 1; 70 (6): e20231321e20231321.

ObjectiveThe aim of this study was to evaluate the prevalence and risk factors related to metabolic dysfunction-associated steatotic liver disease in inflammatory bowel disease patients.MethodsThis is a cross-sectional study conducted on adults with inflammatory bowel disease from 2019 to 2021. Metabolic dysfunction-associated steatotic liver disease encompasses patients with steatosis and at least one cardiometabolic risk factor. Patients with alcohol consumption ≥20 g/day, chronic liver diseases, or methotrexate use were excluded.ResultsAlmost 140 patients were included: 67.1% were female, with a mean age of 49.7±13.7 years, and 63.6% had Crohn's disease. The mean duration of inflammatory bowel disease was 9.7±7.9 years. Metabolic dysfunction-associated steatotic liver disease was observed in 44.3% and advanced liver fibrosis was excluded in 63.5% by Fibrosis-4. Patients with metabolic dysfunction-associated steatotic liver disease were older (p = 0.003) and had a higher number of metabolic syndrome components (2.9±1.1 versus 1.6±1.0; p<0.001), greater abdominal circumference (p<0.001), and body mass index (p<0.001). The only factor related to inflammatory bowel disease associated with metabolic dysfunction-associated steatotic liver disease was disease duration (11.6±9.5 versus 8.3±6.2; p = 0.017). A higher number of metabolic syndrome components and obesity increase by 2.2 times and an altered waist circumference by 2.6 times the occurrence of metabolic dysfunction-associated steatotic liver disease.ConclusionA high prevalence of metabolic dysfunction-associated steatotic liver disease was observed in patients with inflammatory bowel disease, with the main risk factors being associated with metabolic syndrome predicting it, but not with inflammatory bowel disease features and/or its treatment.

24 keywords...

hide…